Watch TVTX. Know when insiders buy.
One email the day a filing lands. Free.
TVTX
Travere Therapeutics, Inc.
52.71
+0.13 +0.25%
USD · Oct 22, 01:21 p.m. ET
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
37
FLAG · insiders 25, shorts 49
Insiders, 90 days
−$79.5M
net selling · 0 buys, 44 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $5BP/E —DIV YIELD —FCF YIELD —REV TTM $591.3M +77.1%NET INCOME −$43.5MNET CASH $71.7M52W 26.79 – 67.52SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $169.6M | +48.2% | 98.7% | $4M | −$34.8M | — | -0.37 | $58.1M | — | — | Aug 4 |
| Q1 2026 · Mar 31 | $127.2M | +55.6% | 98.5% | −$36.9M | −$37.1M | — | -0.40 | −$40.4M | — | — | May 4 |
| Q4 2025 · Dec 31derived | $129.7M | +73.4% | 98.0% | −$32.4M | $2.7M | — | 0.03 | $60.7M | — | — | Feb 19 |
| Q3 2025 · Sep 30 | $164.9M | +162.1% | 99.0% | $24.9M | $25.7M | — | 0.28 | $14.3M | $140K | $14.2M | Oct 30 |
| Q2 2025 · Jun 30 | $114.4M | +111.5% | 98.7% | −$12.7M | −$12.8M | — | -0.14 | $5M | — | — | Aug 4 |
| Q1 2025 · Mar 31 | $81.7M | +97.5% | 94.3% | −$42.7M | −$41.2M | — | -0.47 | −$42.2M | — | — | May 4 |
| Q4 2024 · Dec 31derived | $74.8M | +66.0% | 96.6% | −$60.7M | −$60.3M | — | -0.71 | −$35.7M | — | — | Feb 19 |
| Q3 2024 · Sep 30 | $62.9M | +69.6% | 97.4% | −$56.1M | −$54.8M | −136.4% | -0.70 | −$42.5M | $0 | −$42.5M | Oct 30 |
| Q2 2024 · Jun 30 | $54.1M | — | 96.2% | −$67.7M | −$70.4M | — | -0.91 | −$40.2M | $82K | −$40.3M | Aug 6 |
| Q1 2024 · Mar 31 | $41.4M | — | 96.4% | −$139.2M | −$136.1M | — | -1.76 | −$119M | $0 | −$119M | May 1 |
| Q4 2023 · Dec 31 | $45.1M | — | 89.9% | −$94.2M | −$90.2M | — | -1.18 | −$70.5M | $25K | −$70.5M | Feb 19 |
| Q3 2023 · Sep 30 | $37.1M | — | 96.5% | −$92.6M | $150.7M | — | 1.97 | −$59.1M | $10K | −$59.1M | Oct 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $490.7M | 97.9% | −$62.8M | −$25.5M | -5.2% | -0.29 | $37.8M | — | — | — | — |
| FY2024 · to Dec 31 | $233.2M | 96.7% | −$323.8M | −$321.5M | -137.9% | -4.08 | −$237.5M | — | — | — | — |
| FY2023 · to Dec 31 | $145.2M | 92.1% | −$388.1M | −$111.4M | -76.7% | -1.50 | −$280M | $668K | −$280.7M | — | — |
| FY2022 · to Dec 31 | $109.5M | 96.0% | −$319.8M | −$278.5M | -254.4% | -4.37 | −$186.3M | $191K | −$186.5M | — | — |
| FY2021 · to Dec 31 | $131.8M | 97.1% | −$199.4M | −$180.1M | -136.6% | -3.01 | −$14.8M | $5.1M | −$19.9M | — | — |
| FY2020 · to Dec 31 | $198.3M | 96.9% | −$176.2M | −$169.4M | -85.4% | -3.56 | −$42.7M | $6.8M | −$49.5M | — | — |
Every number comes from Travere Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.